YCT-529

DRUG2 trials

Sponsors

YourChoice Therapeutics, Inc.

Conditions

Male Contraception

Phase 1

First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males

CompletedNCT06094283

YourChoice Therapeutics, Inc.Male Contraception

Start: 2023-12-20End: 2024-06-18Updated: 2024-10-02

Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males

RecruitingNCT06542237

YourChoice Therapeutics, Inc.Male Contraception

Start: 2024-09-11End: 2026-07-31Target: 88Updated: 2026-02-13

Related Papers

YCT-529: a promising oral non-hormonal male contraceptive and its implications for family planning

Annals of Medicine and Surgery2026-02-24

CRISPR-ko screen identifies RARα inhibition as a strategy to increase CD38 expression in multiple myeloma and potentiate anti-CD38 therapy.

Blood2025-11-03

Safety and pharmacokinetics of the non-hormonal male contraceptive YCT-529.

2025-07-22